DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1494)

Diabetic Nephropathy | Unmet Need | Detailed, Expanded Analysis

Diabetic Nephropathy | Unmet Need | Detailed, Expanded Analysis

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Patients with type 2 diabetes ( T2D ) and nephropathy, also known as diabetic nephropathy ( DN ), are at significant risk of developing end-stage renal disease ( ESRD ), a condition associated with extreme morbidity/mortality and high cost of care. Current therapies are unable to prevent progressive renal decline once initial DN sets in. As a result, physicians report substantial unmet need for safe and efficacious therapies for this indication. This unmet need represents significant commercial opportunity, one that drug developers have been quick to realize. Understanding the importance of key efficacy, safety and tolerability, and nonclinical attributes to the prescribing decisions for DN will be paramount to developing a successful therapy.
Questions Answered:

What are the treatment drivers and goals for DN ?
What attributes are key influences, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for DN ?
What are the prevailing areas of unmet need and opportunity in DN ?
What trade-offs across different clinical attributes and price are acceptable to and European endocrinologists and nephrologists for a hypothetical new DN drug?

Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 and 30 European endocrinologists and nephrologists, fielded in January 2017.
Key companies: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, AbbVie, Bayer HealthCare, Janssen
Key drugs: Jardiance, Victoza, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), atrasentan, finerenone, canagliflozin

  • Pub Date: September 2017
  • Author(s): Caitlin Koris, MSPH

Request report

Related reports:
You may also be interested in: